AWAK Technologies is thrilled to announce the publication of the First-In-Human trial results of our sorbent-based wearable #artificial#kidney device in the ISPD (International Society for Peritoneal Dialysis) journal!

The study was conducted in collaboration with Singapore General Hospital‘s Department of Renal Medicine and Duke-NUS Medical School, on 15 patients who were put through multiple sessions of #AWAK dialysis. It was observed that the AWAK device was safe to use with no serious adverse events.

This study not only serves as a great stepping stone for us as we look at improving and further enhancing our device; it also brings us a step closer to our long-term vision of improving the quality of life for #dialysis patients.

Our CEO Suresha Venkataraya adds “It is a long haul, but we started our clinical journey on a good note. I’m confident that our purpose of bringing a paradigm shift in dialysis keeps us going with the next phase of our clinical journey, which is not too far!”

AWAK expresses its gratitude to our board of directors, investors, clinical and manufacturing partners. And Kudos to the incredible AWAK team for their remarkable passion and hard work!

To read the full study, click here: https://lnkd.in/g7jEHBZ
Marjorie Foo , Sheena Gow , Siti Noor Huda , Jason Lim , Peter Haywood , (Victoria) Yue Wang, PhD , Mandar Gori , Suresha Venkataraya
Advanced MedTechVickers Venture Partners